• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Amgen to Acquire Five Prime Therapeutics for $1.9B

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Reed-Lane Facility Virtual Tour

    CureVac, Novartis Ink COVID Vax Mfg. Pact

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    WuXi AppTec Completes OXGENE Acquisition

    Trends in Solid Oral Dosage Delivery
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions

    Innoforce and dMed Enter Development Collaboration

    Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site

    Four Female Leaders Appointed to Cell & Gene CDMO

    Strata Oncology Unveils Strata PATH Trial
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Almac Group

    Reed-Lane

    Baxter BioPharma Solutions

    Emergent BioSolutions

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Almac Group

    Baxter BioPharma Solutions

    Aphena Pharma Solutions

    Emergent BioSolutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Pharma Beat

    Healthcare Costs Run Rampant

    Could Amazon, Berkshire Hathaway and J.P. Morgan Chase be the anti-ballistic missile needed to control and curb rising hea

    Healthcare Costs Run Rampant
    Related CONTENT
    • Mogene
    • Regis Custom Pharma
    • Altasciences
    • Vetio Animal Health
    • Drug Safety Update
    Girish Malhotra, Contributing Editor03.09.18
    The recent announcement from Amazon, Berkshire Hathaway and JP Morgan Chase1,2 to address rising healthcare costs for their employees has caused a bit of an uproar on the healthcare landscape. Healthcare companies and many others have expressed their concerns and doubts about the success of the partnership.3 There will be many “naysayers” and many will pontificate. Their concerns could be real but the time for “creative destruction”4,5,6 on the healthcare landscape has come. It has been long overdue.

    Over the last one hundred years creative destruction/disruption has led to significant innovations in almost every industry. To a major extent pharmaceutical and healthcare industries have escaped this disruption. It is my perspective that time for the needed disruption has come. The banding of ABM (Amazon, Berkshire, Morgan) could signal the start of an alternative healthcare landscape. There will be evolution. Some of the elements that need change are also being discussed.1 The discussion of rising healthcare costs and controlling them is out of the closet. The fact that these three companies, with a combined revenue of about $500 billion dollars per year and over one million employees, are going to explore possibilities of how the costs can be contained and even lowered, will be a good thing.

    The task is going to be challenging, multi-faceted and evolutionary. Not to mention, there will be significant resistance from every cog of the healthcare wheel. The political and economic power of the healthcare industry will be tested. We should not be surprised if legislators, intellectuals and consultants also get in the act to score points.

    For the tie-up to be a success it will require strategic re-modeling of the current business model, rejuvenation of manufacturing practices, supply chain changes and re-allocation of the workforce. Status quo of the current practices is going to be increasingly disrupted and disturbed with every ABM success. Each success will bring in new players to improve the process. Business strategies will change. Technology—artificial and real—along with the process of continuous improvement will play a major role.

    ABM’s effort to lower healthcare costs runs counter to the current operating philosophies of the pharmaceutical, insurers and pharmacy benefit manager companies. A quick look just at the pharmaceuticals tells us part of the story. Most of the revenue growth of the pharmaceutical companies is in the developed countries.7 Lately, pharmaceutical companies, due to their inability to create affordable new drugs that are more effective than the current drugs for the mutually subsidized healthcare systems and affordable to more than 98% of the global population, are depending on high priced orphan drugs, preventing generic entries and are raising prices. Due to political pressures some pharmaceutical companies have opted to less than 10% price increases.8,9 I am not sure how long these strategies will work. ABM is giving the healthcare industry an opportunity to stay afloat. There will be a survival tug of war. My conjecture is fissures in the healthcare citadel will develop and could get wider and thereby lower healthcare costs.

    Other healthcare components would most likely experience similar cost pressures. Since there are multiple elements in healthcare, I am sharing my perspective of the possibilities as they relate to drug prices for pharmaceutical manufacturing only.10

    A recent post, “Comparison of Drug Prices: U.S. vs. India: Their Manufacturing Costs & Opportunities to Improve Affordability,”11 gives us a perspective of drug price differences for generic drugs. A brief review suggests there are tremendous price change possibilities.

    While collecting the pricing information11 I noticed some drug packaging trends that might be worth mentioning. The majority of the drugs in India come in blister pack or foil strips of 10 to 20 counts each. When one asks for a specific drug, the customer receives the prescribed/required number of tablets. Since air-conditioning is not available at every pharmacy, blister pack or foil strips might be preserving the drug from extremes. Such packaging could be used in the developed countries also. There are some advantages with using such packaging including reduced waste, reduced cross contamination if the tablets look alike and speedier drug dispensing. Every cost reduction could be passed on to the patients.

    Opportunities
    Since Amazon is an online store and they are already serving the needs of patients, they could throw in each of the following elements to serve and lower drug costs.
    Local same day delivery could play a major role in Amazon’s business expansion. Through reverse calculation11,12,13 ABM could negotiate with various OTC, generic and even branded companies the best prices they can provide via Amazon.com to their employees and expand to serve others. Reverse calculation will improve price negotiation and incorporation of better technologies to improve product quality, profits and lower costs. The ABM enterprise through Amazon could have more than one supplier for the same drug offerings. It would be a case similar to companies competing for “shelf space” on the basis of product quality and sell price as is being done currently by different producers of the same products on Amazon’s website and at grocery stores. Another significant benefit of ABM’s effort and the drugs being available via Amazon.com will result in drug pricing transparency. Through advanced technology, copay systems of mutually subsidized systems could be incorporated. Single pay systems could also be tested and if successful could be expanded.

    My conjecture is that if companies compete side-by-side for the same product quality they will compete on costs. This also means inclusion of manufacturing technology innovation through “economies of scale,”14,15 which has been shunned in API manufacturing and their formulations.

    FDA will also have to change its review process and approval methods. It will have to develop and promulgate a road map so that the ANDA approval process could be lowered to three months.16,17 NDA approval methods will have to be revisited as well. FDA will face significant internal resistance to such a change but the long-term benefits will outlast the short-term hiccups. Since the “Lower the Healthcare Cost” Genie is out of the bag and is recognized, change will happen. It’s just a matter of time.

    Additionally, FDA’s regulatory quality compliance would still stand. My conjecture is that if companies compete side-by-side for the same product quality they will compete on costs and quality, which means manufacturing technology innovation through inclusion of “economies of scale” in API manufacturing and their formulations.

    With drugs being available via Amazon.com, another significant benefit of ABM’s effort will be drug-pricing transparency that is hidden from patients in mutually subsidized healthcare systems.

    Quoting the Wall Street Journal’s editorial board, “…health care is long overdue for a shake up, and the leaders of these companies—Mr. Buffett, Jeff Bezos and Jamie Dimon—deserve credit for jumping in. The public would be the beneficiary if this trio can figure out how to lower costs and increase quality, and the odds are better with them than another political intervention.”6

    Since change in healthcare is much needed by the constituents of our country it will also be a test of our legislators’ short- and long-term interests and alliances. Political and economic pressures will be tremendous.

    Only time will tell who wins and who does not and by how much. One thing for sure is that each segment of healthcare value chain—pharmaceutical development, manufacturing, distribution and insurers, providers, hospitals—will have to review/alter their modus operandi to lower their costs and improve quality of products/services they provide.

    Assembly line methods e.g. cataract in India, knee replacements and other procedures might have to be adopted, streamlined or considered to improve and lower healthcare costs. Drug affordability is an issue and will become increasingly an important part of the discussion as America ages. Healthcare providers will have to forgo their latent prevailing sentiment that patients will pay the highest price to get well and extend their life.

    Many will be rooting for ABM’s success, but there will be many others creating obstacles along the way. 

    References
    1. Triple Threat: Amazon, Berkshire, JPMorgan Rattle Health-Care Firms, The Wall Street Journal, January 30, 2018, Accessed January 31, 2018
    2. If Amazon And Buffett Lift Veil On Health Prices, Insurers Are In Trouble, Forbes.com, January 31, 2018, Accessed January 31, 2018
    3. JPMorgan to Banking Clients: Joint Health-Care Venture Is No Threat, WSJ.COM, February 4, 2018, Accessed February 4, 2018
    4. Creative destruction: https://en.wikipedia.org/wiki/Creative destruction Accessed January 31, 2018
    5. Malhotra, Girish: Is “Creative Destruction” the way to go for the Pharmaceuticals? Profitability through Simplicity, December 11, 2008, Accessed February 5, 2018
    6. Welcome to the Health-Care Jungle, WSJ.COM February 1, 2018, Accessed February 5, 2018
    7. Malhotra, Girish: An Alternate Look at the Pharmaceutical World Revenues and Drug Affordability, Pages 2-5, www.gmpnews.net, Autumn 2017, Manufacturing Chemist, Volume 88, Number 10, October 2017, Pg. 28-32
    8. Facing Criticism, Drug Makers Keep Lid On Price Increases, WSJ.COM [https://www.wsj.com/articles/facing-criticism-drug-makers-keep-lid-on-price-increases-1488157893], February 26, 2017, Accessed February 5, 2018
    9. US pharma industry holds to price-cap pledge, Pharmaceutical Technology [https://www.pharmaceutical-technology.com/comment/us-pharma-industry-holds-price-cap-pledge/], January 5, 2018, Accessed February 5, 2018
    10. Malhotra, Girish: Comparison of Drugs Prices: US vs. India; Their Manufacturing Costs & Opportunities to Improve Affordability, Profitability through Simplicity, January 18, 2018
    11. Malhotra, Girish: May Day May Day: Can Someone Help and Lower Drug Prices?, Profitability through Simplicity, May 1, 2015, Accessed February 5, 2018
    12. Malhotra, Girish: A Blueprint for Improved Pharma Competitiveness, Contract Pharma, September 8, 2014 Accessed February 6, 2018
    13. Malhotra, Girish: Can An Alliance Between US Pharmaceutical Benefit Managers (1) and Make in India (2) Lead to Lower Global Drug Prices? Profitability through Simplicity, June 17, 2015 Accessed February 6, 2018
    14. Malhotra, Girish: Recent Posts That Relate to Pharmaceuticals and Chemicals-I, Profitability through Simplicity, 2013, Accessed February 6, 2018
    15. Malhotra, Girish: Neglected Tropical Disease (Infectious Diseases) Drugs: What are they telling us about Innovations! Profitability through Simplicity, March 7, 2012, Accessed February 6, 2018
    16. Malhotra, Girish: Can the Review and Approval Process for ANDA at USFDA be Reduced from Ten Months to Three Months? Profitability through Simplicity, March 25, 2017
    17. Malhotra, Girish: ANDA (Abbreviated New Drug Application) / NDA (New Drug Applications) Filing Simplification: Road Maps are a Must, Profitability through Simplicity, May 11, 2017

    Girish Malhotra
    Contributing Editor

    Girish Malhotra, president and founder of EPCOT International, has more than 45 years of industrial experience in pharmaceuticals, specialty, custom, fine chemicals, coatings, resins and polymers, additives in manufacturing, process and technology development and business development. girish@epcotint.com; Tel: 216-223-8763.
    Related Searches
    • fine chemicals
    • packaging
    • orphan
    • api manufacturing
    Suggested For You
    Mogene Mogene
    Regis Custom Pharma Regis Custom Pharma
    Altasciences Altasciences
    Vetio Animal Health Vetio Animal Health
    Drug Safety Update Drug Safety Update
    The Logistics Behind Personalized Medicine Delivery The Logistics Behind Personalized Medicine Delivery
    BioPlan Associates BioPlan Associates' 15th Annual Bio Mfg. Study is Open
    Pii Receives 7 Market Approvals from FDA in 2017 Pii Receives 7 Market Approvals from FDA in 2017
    Sobi Receives IND Acceptance from FDA Sobi Receives IND Acceptance from FDA
    Phillips-Medisize to Expand Little Rock Facility Phillips-Medisize to Expand Little Rock Facility
    PixarBio, Particle Sciences Enter Manufacturing Agreement PixarBio, Particle Sciences Enter Manufacturing Agreement
    FDA Accepts Novartis FDA Accepts Novartis' sNDA for Stage III Melanoma Treatment
    Ensuring The Quality of Clinical Trial Data Ensuring The Quality of Clinical Trial Data
    Melinta Buys Infectious Disease Unit from The Medicines Company Melinta Buys Infectious Disease Unit from The Medicines Company
    Vetter Expands Secondary Packaging Capacities Vetter Expands Secondary Packaging Capacities

    Related Pharma Beat

    • The Changing Approach to Design: Five Ways to Achieve Warp Speed

      The Changing Approach to Design: Five Ways to Achieve Warp Speed

      Revisiting facility design and construction based on today’s biopharmaceutical industry needs.
      Jarrod Wrampe, Contributing Editor 10.14.20

    • The “Three Cs” of C(D)MO Selection

      The “Three Cs” of C(D)MO Selection

      Plus, what does it take for contract organizations to fall in the “Goldilocks” zone for pharmaceutical companies?
      Valdas Jurkauskas, Ph.D., Akebia Therapeutics 07.15.20

    • Supply Chain
      Supply Chain Disruptions

      Supply Chain Disruptions

      The implications of Sandoz’ recent recalls.
      Ed Silverman, Guest Columnist 10.15.19


    • cGMP Manufacture
      The Good, The Bad, and The Ugly Complexities of Pharmaceutical Manufacturing

      The Good, The Bad, and The Ugly Complexities of Pharmaceutical Manufacturing

      What does it really take to develop, design, scale-up, commercialize and manage continuous processes?
      Girish Malhotra, Contributing Editor 06.12.18

    • Opportunities to Lower Drug Prices and Improve Affordability

      Opportunities to Lower Drug Prices and Improve Affordability

      From creation (manufacturing) to consumption (patient)
      Girish Malhotra, Contributing Editor 05.08.18

    • Drug Development

      NSAIDs – Friend or Foe?

      Although widely used for years, NSAIDs have side effects that could eventually change their OTC status
      Adele Graham-King, Contributing Editor 06.06.17


    • Drug Development | Drug Discovery
      Tackling TB Resistance

      Tackling TB Resistance

      The TB Alliance is partnering with universities, government agencies, public agencies and a small number of pharma compani
      Adele Graham-King, Contributing Editor 05.09.17

    • Drug Development

      Could Nuts Ward Off Cancer?

      Recent research looks into the anti-cancer properties of various nuts
      Adele Graham-King, Contributing Editor 04.03.17

    • Drug Delivery | Drug Development | R&D

      ‘Smart’ Heparin Delivery Could Self-Modulate

      A group of researchers have spent the past two years investigating self-controlling dosing and monitoring systems
      Adele Graham-King, Contributing Editor 01.26.17


    • Drug Development | Drug Discovery | R&D

      Is Nicotine Such a ‘Bad Boy’?

      Investigating this controversial compound’s potential health benefits
      Adele Graham-King, Contributing Editor 11.09.16

    • Drug Development | Drug Discovery | R&D

      Blackberry Wine: Could it Help Your Diabetes?

      Recent research points towards the positive impact ‘berry wine’ might have on diabetes
      Adele Graham-King, Contributing Editor 10.11.16

    • Can Greens Cure Cancer?

      Long touted for its health properties, broccoli is being studied for its potential curative effects in cancer
      Adele Graham-King, Contributing Editor 07.12.16


    • Chemistry | Drug Development
      Anyone Fancy a Beer?

      Anyone Fancy a Beer?

      The centuries-old brew continues to be investigated for its medicinal properties
      Adele Graham-King, Contributing Editor 05.05.16

    • Drug Development

      Chipping Away at the Old Cancer Block

      Advances in cancer treatment continue to march towards finding a cure
      Adele Graham-King, Contributing Editor 04.05.16

    • Where is The Silver Bullet for Alzheimer’s?

      There continues to be a lack of progress with regards to a cure for AD.
      Adele Graham-King, Contributing Editor 03.09.16

    Trending
    • Catalent Acquires Delphi Genetics
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • AbbVie Opts To Acquire Mitokinin
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • WuXi AppTec Completes OXGENE Acquisition
    Breaking News
    • Amgen to Acquire Five Prime Therapeutics for $1.9B
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    • CureVac, Novartis Ink COVID Vax Mfg. Pact
    • Innoforce and dMed Enter Development Collaboration
    • Matica Biotechnology Breaks Ground on Cell and Gene Therapy Site
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Statins May Contribute to Vascular Calcification by Inhibiting Vitamin K-Dependent Proteins
    Coatings World

    Latest Breaking News From Coatings World

    Chromaflo Technologies Adds Benjamin Woeste as Territory Sales Manager
    Maroon Group Acquires Cary Company's Raw Materials, Specialty Chemicals Distribution Business
    Matt Fogel Named Mule-Hide's Territory Manager – Southern Virginia
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    EchoNous Expands Its Kosmos Hardware Platform
    Medtronic Begins Trial to Assess Novel Ablation Tech to Treat AFib
    Europe's Cross-Border Medtech Deal Activity Rises in Q4 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Amgen to Acquire Five Prime Therapeutics for $1.9B
    Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    CureVac, Novartis Ink COVID Vax Mfg. Pact
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Estée Lauder Establishes Equity and Engagement Center of Excellence
    L'Oreal On How It Will Shape Beauty's Future at Today's Transparency Summit
    C.O. Bigelow Earns Praise as NYC's Oldest Family-Run Apothecary
    Happi

    Latest Breaking News From Happi

    Avon Launches Vegan Skin Care Line
    Inolex Appoints VP Marketing
    Decorté Launches AI Diagnostics in US
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Springfield Solutions highlights digital label embellishments
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Bioventus Appoints Managing Director, China and Asia Pacific
    Full-Year Sales Down 12 Percent at Zimmer Biomet
    Lincotek Medical Expands Coatings and Additive Capacity
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login